A detailed history of Legal & General Group PLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 4,387 shares of CADL stock, worth $24,084. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,387
Previous 3,099 41.56%
Holding current value
$24,084
Previous $17,000 29.41%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025

BUY
$4.39 - $6.04 $5,654 - $7,779
1,288 Added 41.56%
4,387 $22,000
Q1 2025

May 15, 2025

BUY
$5.65 - $12.21 $5,096 - $11,013
902 Added 41.06%
3,099 $17,000
Q2 2024

May 29, 2025

SELL
$1.68 - $14.0 $1,515 - $12,628
-902 Reduced 29.11%
2,197 $13,000
Q2 2024

Aug 14, 2024

BUY
$1.68 - $14.0 $3,690 - $30,758
2,197 New
2,197 $13,000

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $159M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.